Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine
On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…
Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
On Oct. 18, 2021, Pfizer and BioNTech announced that the European Medicines Agency’s Committee for Human Medicinal Products…
Pfizer and BioNTech submitted data to EMA for vaccination of children 5 to <12 years of age with COMIRNATY
On Oct. 15, 2021, Pfizer and BioNTech announced they had submitted data supporting the vaccination of children 5…
Pfizer and BioNTech received CHMP positive opinion for COVID-19 vaccine booster in the European Union
On Oct. 4, 2021, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine
On Sept. 29, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…
Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidate
On Sept. 28, 2021, Sanofi announced that it had terminated plans for its own mRNA-based COVID-19 vaccine given…
Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to <12 years of age
On Sept. 28, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…
Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine booster
On Sept. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) has authorized…
Biotechnology | COVID-19 | Genomics | HIV | Vaccine
Winners of 2022 Breakthrough Prizes In Life Sciences announced
On Sept. 22, 2021, the Breakthrough Prize Foundation and its founding sponsors announced the 2022 winners of the…
Pfizer and BioNTech expanded U.S. collaboration to provide 500 million additional COVID-19 vaccine doses to poorest countries
On Sept. 22, 2021, Pfizer and BioNTech announced plans to expand their agreement with the U.S. government by…
Pfizer and BioNTech announced positive topline results from pivotal trial of COVID-19 vaccine in children 5 to 11 years
On Sept. 20, 2021, Pfizer and BioNTech announced results from a Phase 2/3 trial showing a favorable safety…
Biotechnology | COVID-19 | FDA | Pharmaceutical | Therapeutics | Vaccine
Pfizer and BioNTech submitted a variation to EMA with data in support of a booster dose of COMIRNATY
On Sept. 6, 2021, Pfizer and BioNTech announced that they had submitted a variation to the European Medicines…
WHO, Germany opened Hub for Pandemic and Epidemic Intelligence in Berlin
On Sept. 1, 2021, the World Health Organization inaugurated the new WHO Hub for Pandemic and Epidemic Intelligence…
Pfizer and BioNTech announced collaboration with Brazil’s Eurofarma to manufacture COVID-19 vaccine doses
On Aug. 26, 2021, Pfizer and BioNTech announced the signing of a letter of intent with Eurofarma Laboratorios,…
Pfizer and BioNTech initiated rolling submission of SBLA to U.S. FDA for booster dose of COMIRNATY in individuals 16 and Older
On Aug. 25, 2021, Pfizer and BioNTech announced the initiation of a supplemental Biologics License Application (sBLA) to…
U.S. FDA approved first COVID-19 vaccine
On Aug. 23, 2021, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine, known…
Pfizer-BioNTech COVID-19 vaccine COMIRNATY received full U.S. FDA approval for individuals 16 years and older
On Aug. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) approved the…
Vaccines still effective against Delta variant of concern, says Oxford-led study of the COVID-19 Infections Survey
On Aug. 19, 2021, the University of Oxford reported that obtaining two vaccine doses remained the most effective…
Pfizer and BioNTech announced submission of initial data to FDA to support booster dose of COVID-19 vaccine
On Aug. 16, 2021, Pfizer and BioNTech announced that they had submitted Phase 1 data to the U.S….
NIH launched study of third COVID-19 vaccine dose in kidney transplant recipients
On Aug. 10, 2021, the National Institutes of Health (NIH) announced that a pilot study had begun to…
Pfizer and BioNTech to supply U.S. Government with additional 200 million doses of COVID-19 vaccine
On Jul. 23, 2021, Pfizer and BioNTech announced that the U.S. government had purchased an additional 200 million…
Pfizer and BioNTech announced collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses in Africa
On Jul. 21, 2021, Pfizer and BioNTech announced the signing of a letter of intent with The Biovac…
Biotechnology | COVID-19 | FDA
U.S. FDA granted Priority Review for Biologics License Application for Pfizer-BioNTech COVID-19 vaccine
On Jul. 16, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had granted…
10 million doses of mRNA-based COVID-19 vaccine supplied to Taiwan Region
On Jul. 12, 2021, BioNTech announced that Fosun Industrial Co. had reached advance procurement agreements for the mRNA-based…
Pfizer and BioNTech provided update on booster program in light of the Delta-variant
On Jul. 8, 2021, Pfizer and BioNTech announced encouraging data in the ongoing booster trial of a third…
XPhyto supplied 10 test centers in Berlin with 25-minute COVID-19 PCR test
On Jun. 30, 2021, XPhyto announced that it had signed a master supply agreement with Beovita and Tackleberries,…
Mixed Oxford/Pfizer vaccine schedules generated robust immune response against COVID-19
On Jun. 28, 2021, researchers running the University of Oxford-led Com-COV study reported that alternating doses of the…
Pfizer and BioNTech provided 500 million doses of COVID-19 vaccine to U.S. Government for donation to poorest nations
On Jun. 10, 2021, Pfizer and BioNTech announced plans to provide the U.S. government at a not-for-profit price…
Pfizer and BioNTech received first authorization in European Union for COVID-19 vaccine in adolescents
On May 28, 2021, Pfizer and BioNTech announced that the Conditional Marketing Authorization for COMIRNATY in the European…
Study initiated exploring coadministration of 20-valent pneumococcal conjugate vaccine with third dose of Pfizer-BioNTech COVID-19 vaccine
On May 24, 2021, Pfizer announced that the first enrolled subjects had received their immunizations as part of…